Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial

PURPOSE: The efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily (OD) compared with insulin glargine U100 (IGlar) OD over 52 weeks in insulin-naïve adults with type 2 diabetes mellitus (T2DM) was investigated. METHODS: In this open-label, parallel-group treat-to-target trial,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Ajay, Franek, Edward, Wise, Jonathan, Niemeyer, Marcus, Mersebach, Henriette, Simó, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070831/
https://www.ncbi.nlm.nih.gov/pubmed/27760129
http://dx.doi.org/10.1371/journal.pone.0163350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070831/
https://www.ncbi.nlm.nih.gov/pubmed/27760129
http://dx.doi.org/10.1371/journal.pone.0163350

Ejemplares similares